Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for... see more

Recent & Breaking News (NYSE:MRK)

Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop for Futility and Patients to Discontinue...

Business Wire November 9, 2020

Pappas Capital Portfolio Company VelosBio to be Acquired by Merck

PR Newswire November 5, 2020

LYNPARZA® (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

Business Wire November 5, 2020

LYNPARZA® (olaparib) Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Business Wire November 5, 2020

Merck to Acquire VelosBio

Business Wire November 5, 2020

Merck Announces Third-Quarter 2020 Financial Results

Business Wire October 27, 2020

Merck Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination Efforts

Business Wire October 22, 2020

Merck to Present New Data from its Extensive Infectious Diseases and Vaccines Pipeline and Portfolio During IDWeek 2020

Business Wire October 21, 2020

Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine

Business Wire October 20, 2020

Merck Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With KEYTRUDA in Advanced Non?Small Cell Lung Cancer

Business Wire October 16, 2020

Health Canada Approves KEYTRUDA® (pembrolizumab) as First-line Treatment for Patients with Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma

Canada NewsWire October 15, 2020

FDA Approves Expanded Indication for Merck's KEYTRUDA® (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Business Wire October 15, 2020

Merck Issues 2019/2020 Corporate Responsibility Report

Business Wire October 14, 2020

Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With HIV-1 Infection

Business Wire October 8, 2020

Merck Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointed as President, Merck Research Laboratories

Business Wire October 2, 2020

Merck to Present New Data from the Company's Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020

Business Wire October 1, 2020

Merck to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October 27

Business Wire October 1, 2020

Merck Animal Health Supports Rabies Elimination by 2030 on World Rabies Day

Business Wire September 28, 2020

NEXPLANON® Contraceptive Arm Implant Now Available for Use in Canada

Canada NewsWire September 24, 2020

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer

Business Wire September 21, 2020